Patent Grant: Longeveron has been granted a patent by the USPTO covering the use of its proprietary mesenchymal stem cells (MSCs) for treating female sexual dysfunction, with rights extending to 2038, thereby enhancing the company's competitive edge in regenerative medicine.
Market Demand: Female sexual dysfunction affects up to 46% of women and becomes increasingly common with age, indicating a significant unmet medical need that Longeveron's treatment could address, potentially capturing a growing market.
Commercialization Prospects: The company anticipates entering into licensing or partnership agreements to advance the development and commercialization of its stem cell therapy, which is expected to create new revenue streams and market opportunities.
Technological Advantage: Longeveron's laromestrocel (LOMECEL-B®) product is derived from bone marrow cells of young healthy adults and may exhibit multiple mechanisms of action, including anti-inflammatory and regenerative effects, making it applicable to various rare and aging-related diseases.
LGVN
$0.6028+Infinity%1D
Analyst Views on LGVN
Wall Street analysts forecast LGVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LGVN is 3.50 USD with a low forecast of 3.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast LGVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LGVN is 3.50 USD with a low forecast of 3.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.553
Low
3.00
Averages
3.50
High
4.00
Current: 0.553
Low
3.00
Averages
3.50
High
4.00
Roth Capital
Buy
downgrade
$10 -> $3
2025-08-15
Reason
Roth Capital
Price Target
$10 -> $3
2025-08-15
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Longeveron to $3 from $10 and keeps a Buy rating on the shares. The firm's price target cut reflects Q2 results and the dilutive equity financing earlier this week, though Longeveron remains an underappreciated firm despite its first-mover advantage in HLHS, or Hypoplastic Left Heart Syndrome, the analyst tells investors in a research note.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$10
2025-03-21
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$10
2025-03-21
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$10
2025-03-03
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$10
2025-03-03
Reiterates
Strong Buy
Reason
About LGVN
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
